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Abstract
Multiple myeloma (MM) is incurable and invariably becomes resistant to chemotherapy. Although 
the mechanisms remain unclear, hypoxic conditions in the bone marrow have been implicated in 
contributing to MM progression, angiogenesis, and resistance to chemotherapy. These effects 
occur via adaptive cellular responses mediated by hypoxia-inducible transcription factors (HIFs), 
and targeting HIFs can have anti-cancer effects in both solid and hematological malignancies. 
Here, it was found that in most myeloma cell lines tested, HIF1α, but not HIF2α expression was 
oxygen dependent and this could be explained by the differential expression of the regulatory 
prolyl-hydroxylase isoforms. The anti-MM effects of a sequence-specific DNA-binding pyrrole-
imidazole polyamide (HIF-PA), that disrupts the HIF heterodimer from binding to its cognate 
DNA sequences, were also investigated. HIF-PA is cell permeable, localizes to the nuclei, and 
binds specific regions of DNA with an affinity comparable to that of HIF transcription factors. 
Most of the MM cells were resistant to hypoxia-mediated apoptosis, and HIF-PA treatment could 
overcome this resistance in vitro. Using xenograft models, it was determined that HIF-PA 
significantly decreased tumor volume and increased hypoxic and apoptotic regions within solid 
tumor nodules and the growth of myeloma cells engrafted in the bone marrow. This provides a 
rationale for targeting the adaptive cellular hypoxic response of the O2-dependent activation of 
HIFα using polyamides.
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INTRODUCTION
Multiple myeloma (MM) is an incurable disease of malignant plasma cells characterized by 
high rates of relapse and resistance to drug therapies (1–3). The reasons why this disease is 
so difficult to cure is unclear, but the bone marrow (BM) microenvironment is known to 
confer critical growth and survival advantages that protect tumor cells from apoptosis-
inducing stressors (4, 5). The BM is hypoxic (p02 ~10–30 mmHg) when compared to most 
other tissues (pO2 ~85–150 mmHg) (6) and paradoxically, while oxygen stress can kill 
tumor cells (7), low-oxygen conditions also promote tumor progression (8), angiogenesis 
(9), and resistance to chemotherapy (10). These pro-survival responses to low oxygen 
tension are regulated by adaptive cellular responses mediated by several oxygen-sensitive 
transcription factors; the most important of these being the hypoxia-inducible factors (HIFs) 
(for review see (11)). HIFs are composed of a constitutively expressed β-subunit (HIF1β/
ARNT) and inducible α-subunits (HIF1α, 2α, and 3α) that are responsive to oxygen levels 
and are regulated via proteosome-mediated degradation. Briefly, under “normoxic” 
conditions, the HIFα subunits are hydroxylated by a number of closely related prolyl-
hydroxylase domain proteins (PHD1-3) that results in recognition of the α-subunit by the 
von Hippel-Lindau tumor suppressor (VHL), and its subsequent ubiquination and rapid 
degradation by the proteosome. This normally maintains the HIFα-subunits at very low 
levels in the cell. Under hypoxic conditions (pO2 <50 mmHg), the proline-hydroxylase 
activity is inhibited and HIFα degradation is not initiated (12). This allows dimerization of 
the α and β-subunits and the translocation and binding of HIF to the hypoxic response 
elements (HRE), thereby inducing gene transcription of hypoxia related survival and 
angiogenic factors.
It has been shown that heightened expression of pro-angiogenic factors (such as VEGF) and 
increased microvessel density within myeloma tumors is strongly correlated with disease 
development and progression, as well as being predictive of poor patient prognosis (13–16). 
This provided a rationale for using VEGF-targeting drugs, such as bevacizumab (Avastin), 
to attempt to inhibit angiogenesis and increase hypoxic stress in MM tumors, although only 
modest anti-tumor effects were observed (17). These results call into question the overall 
effectiveness of targeting angiogenesis as a mono-therapeutic strategy for treating MM in 
the clinic. Noting that the increase of hypoxia within the tumor bed following inhibition of 
VEGF results in the subsequent activation of the adaptive hypoxic response and induction of 
survival factors may provide an explanation for these underwhelming effects. Under this 
hypothesis, we would argue that these resultant hypoxic conditions are actually supportive 
of MM progression (because low O2 represents a natural component of the bone marrow 
niche in which myeloma engraft) by maintaining hyperactive HIF activity. Thus, rather than 
killing the tumor cells, inhibition of angiogenesis may actually facilitate a pro-survival 
adaptive hypoxic response through HIF activation. If true, then targeting the specific HIF-
mediated response to hypoxia may be a more effective anti-myeloma therapy than targeting 
VEGF or angiogenesis alone. In fact, there are a number of different hypoxia and HIF 
targeting strategies currently being tested in MM with varying levels of success (18).
In this study, we tested the effects of inhibiting the hypoxic adaptive response using a 
synthetically derived, sequence-specific DNA-binding Py-Im polyamide (PA) composed of 
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the aromatic rings of N-methylpyrrole and N-methylimidazole amino acids designed to 
recognize and interfere with HIF binding to HRE sequences within the minor grove of the 
DNA helix (19). We found that under low oxygen culturing conditions, most myeloma cell 
lines were relatively resistant to hypoxia-mediated apoptosis and that HIF1α, but not HIF2α, 
was upregulated in an oxygen-dependent manner. Treatment of MM cells with our HIF-
polyamide (HIF-PA) overcame resistance to hypoxia-mediated apoptosis in vitro as well as 
inhibited the transcription of multiple hypoxia-induced genes. We also found that 
combination treatment with HIF-PA polyamides (to inhibit gene transcription) and the 
mTOR inhibitor rapamycin (to inhibit gene translation) was markedly more effective at 
overcoming resistance to hypoxia-mediated apoptosis in MM cells. In additional 
experiments, we used xenograft models to study the anti-MM effects of Py-Im polyamide 
treatment on MM tumors in vivo and found that Py-Im polyamides were well tolerated by 
the mice and had a marked anti-tumor effect characterized by a significant increase in 
hypoxia as well as concomitant increases in apoptotic and necrotic regions within solid 
tumor nodules as well as inhibition of myeloma growth in tumors engrafted in the BM. 
Altogether, these data suggest that sensitivity of myeloma to polyamide therapy may be 
related to the inhibition of gene expression induced by the oxygen-dependent activation of 
HIF1α (but not necessarily HIF2α) and provides a rationale for targeting the adaptive 
hypoxic responses in MM using these compounds.
MATERIALS AND METHODS
Cell lines and reagents
All cell lines were purchased from ATCC and maintained at 37°C and 5% CO2 (“normoxic” 
condition) unless noted. The cell lines were validated using the Johns Hopkins Genetic Core 
Research Facility (Baltimore, MD) and stock aliquots were stored under liquid nitrogen. 
Testing for mycoplasma was performed using a mycoplasma PCR detection kit (Sigma-
Aldrich, St Louis, MO). Py-Im polyamides were synthesized by solid-phase methods on 
Kaiser oxime resin (Nova Biochem, Billerica, MA) (20). The tested polyamide, HIF-PA, 
targets the sequence 5′-WTWCGW-3′ (W=A or T) and modulates a subset of hypoxia-
induced genes, whilst the control polyamide (CO-PA) recognizes the non-HRE sequence 5′-
WGGWCW-3′. Enzyme-linked immunosorbent assay (ELISA) kits specific for human 
VEGF was purchased from R&D Systems (Minneapolis, MN). The Hypoxyprobe-1 kit was 
purchased from HPI Inc (Burlington, MA). Cellular apoptosis was measured by flow 
cytometry using a cleaved caspase-3 kit (BD Biosciences, San Jose, CA). Small inhibitory 
RNA (siRNA) for HIF1α (Silencer Select siRNA ID# s6539, gene ID# 3091) and scrambled 
control RNA (Silencer Select negative control #1 siRNA) were purchased from Ambion 
(Grand Island, NY). Cells were transfected with siRNA using Lipofectamine-2000 (Life 
Technologies, Grand Island, NY).
Immunoblots
Protein was isolated and western blot analysis was performed as described previously (21). 
Nuclear and cytoplasm fractions were isolated using the Thermo Scientific NE-PER™ 
Nuclear and Cytoplasmic Extraction Kit (Rockford, IL) following the manufacturers 
instruction. HIF1α antibody (clone 54/HIF1) was purchased from BD Biosciences. β-tubulin 
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(clone H-235), LaminA/C (clone 14/LaminAC), BCL-XL (clone H-5), Survivan (clone 
D-8), BNIP3 (clone ANa40), BCL-2 (clone C-2), goat anti-mouse and goat anti-rabbit IgG 
horseradish peroxidase-conjugated antibodies were purchased from Santa Cruz 
Biotechnology (Dallas, TX). BID (rabbit polyclonal), BAX (rabbit polyclonal), AKT-total 
(clone C67E7), AKT-S473 (clone D9E) and AKT-T308 (clone C31E5E) and the P70-total, 
P70-T421/S424, and P70-T389 antibody kits were purchased from Cell Signaling 
Technology (Danvers, MA). MCL-1 (clone 542808) was purchased from R&D systems. 
REDD1 (clone 1G11) was purchased from Bethyl Laboratories (Montgomery, TX). The 
EGLN1/PHD2 (rabbit polyclonal), EGLN3/PHD3 (mouse polyclonal), EGLN3/PHD3 
positive control (an EGLN3/PHD3 over expressing lysate from HEK293T cells), HIF2α 
(rabbit polyclonal), and Factor inhibiting HIF1 (FIH) antibodies (clone 162C) were 
purchased from NOVUS Biologicals (Littleton, CO).
Hypoxia-treatments
For induction of hypoxia, MM cells were cultured in a humidified Hypoxygen hypoxia 
chamber (Grandpair, Heidelberg, Germany). Variable pO2 levels were established in the 
hypoxia chamber from 2-0.1% O2, and 5% CO2 at 37 °C. Oxygen levels were regularly 
tested and calibrated using the manufacturer’s protocol.
Generation of hypoxia response element luciferase-expressing (HRE-LUC) cell lines
HRE-LUC reporter MM cell lines (8226, U266, OPM-2) were generated by stably 
transducing cells using the Cignal lentiviral kit (Qiagen, Valencia, CA) followed by 
selection with hygromycin (350 mg/ml). For the orthotropic xenograft studies, other 
luciferase-expressing 8226 cells (8226-LUC) were stably transfected with the pGL4.5 
luciferase reporter vector (Promega, San Louis Obispo, CA) using an AMAXA Nucleofector 
Kit (Lonza, Koln Germany) followed by selection with hygromycin (350 mg/ml). The in 
vitro luciferase activity was confirmed and measured using the dual-luciferase reporter assay 
kit (Promega, San Louis Obispo) in a luminometer. The in vivo luciferase activity was 
measured using the VivoGlo luciferine substrate (Promega).
Real time PCR
Quantitative expression of VEGF was carried out by quantitative real time PCR. RNA was 
isolated using Triazol (Life Technologies, Carlesbad, CA) and cDNA was synthesized using 
cDNA synthesis kit (Life Technologies). VEGF mRNA was amplified using VEGF primers 
(Life Technologies) in an ABI 7300 real time PCR machine (Life Technologies). The 
Applied Biosystems® TaqMan® Array Human Hypoxia 96-well Plate was used to test for 
changes in hypoxia signaling associated genes.
Animals
Male NOD/SCID or NOG mice (4–6 weeks old) were obtained from Jackson Laboratories 
(Bar Harbor, ME, USA). All animal studies were conducted in accordance with protocols 
approved by the Institutional Animal Care and Use Committed (IACUC) of the Greater Los 
Angeles Veterans Administration Healthcare System (GLA-VAHS).
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SQ Xenograft Model
We used the murine myeloma xenograft model of Leblanc et al (22) with minor 
modifications (21). The 8226 cells (10 × 106 cells/mouse) were mixed with matrigel (BD 
biosciences) then injected subcutaneously into the right flank (200 μl/mouse) of the mice. 
The mice were monitored and randomized into drug treated or control groups (10 mice/
group) when the tumor volume reached approximately 300–500 mm3. The Py-Im polyamide 
solution was prepared as previously described (23). Mice were given HIF-PA injections IP 
every other day for a total of 5 injections. The tumor volume was measured using calipers 
(width and length) using the formula W2 × (L/2) (21, 24) every other day during the course 
of the experiment.
Orthotopic Xenograft Model
8226-LUC cells were injected (10 × 106 cells/mouse) through the tail vein (200 μl/injection). 
In our initial experiments, the localization of human 8226 myeloma cell lines in the bone 
marrow was determined by two methods: (1) flow cytometry staining of bone marrow 
aspirates from the femurs of mice using FITC labeled anti-human CD45 antibodies (BD 
Biosciences) and (2) immunohistochemistry of femurs using anti-human CD45 antibodies. 
Real time 8226-LUC engraftment in the bone marrow was measured in anesthetized mice 
given an IP injection of VivoGlo luciferin substrate (100 mg/kg mouse) and then monitored 
for luciferase activity in the skeleton using a Perkin-Elmer IVIS XRMS small animal 
imaging system. Luciferase activity in the skeleton of mice challenged with 8226-LUC was 
typically observed between day +15 and day +20 post challenge. Once a positive 
bioluminescent signal was observed, the animals were randomized into groups (6–8 animals/
group) and were treated with HIF-PA or vehicle control as described above, except a total of 
6 injections were given, rather than 5. The luciferase activity was measured twice/week as 
described above and the change in average radiance (photons/sec/cm2/steradian) was 
measured and analyzed using the LivingImage version 4.4 imaging software.
Immunohistochemistry
For studies in our SQ model, 24 hours after the last injections, the mice were euthanized and 
the tumor mass was excised. The tumor was bisected using a razor blade: one half of the 
tumor was immediately placed in 10% buffered formaldehyde overnight, and the other half 
was flash frozen for protein extraction. Formaldehyde fixed tumors were embedded in 
paraffin and cut into 5 μm-thick serial sections using standard histological procedures. 
Immunohistochemical staining with cleaved caspase 3, and Hypoxyprobe (pimonidazole) 
(HPI Inc) was conducted using standardized automated methods.
Morphometric Analysis
IHC analysis was performed on tissue sections with a Nikon Microphot-SA microscope 
(Melville, NY, USA) equipped with plan-apochromat lenses (20X and 40X). A Diagnostic 
Technologies digital camera, model SPOT-RT was used to capture images with a resolution 
of 1520 × 1080 pixels. Fields were selected by reviewing the slides at low power by a 
researcher (VM) blinded to the treatments. Multiple non-overlapping fields were identified 
for analysis of regions of hypoxia/necrosis and apoptotic index at higher powers within these 
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areas of interest. ImageJ software (NIH, USA) was used to measure percent of hypoxia 
stained tumor sections. Final images for publication were prepared using Adobe Photoshop 
software.
Oncomine Analysis
The expression level of PHD2/EGLN1 and PHD3/EGLN3 genes in normal, MGUS and MM 
tumors were analyzed using Oncomine, a cancer microarray database and web-based data-
mining platform (25). In order to reduce our false discovery rate, we selected p<0.0001 as a 
threshold. We analyzed the results for p-values and fold change of our genes of interest.
Statistics
Data was screened for consistency and quality by both graphical (histograms, scatter plots) 
and analytical methods (descriptive statistics). Variables were analyzed using generalized 
linear models (GLM) such as ANOVA and t-tests. The effect of combining HIF-PA with 
rapamycin on induction of apoptosis was assessed by the median effect method using 
Calcusyn Software Version 1.1 (Biosoft, Cambridge, United Kingdom). Combination 
indices (CI) values were calculated using the most conservative assumption of mutually 
nonexclusive drug interactions. CI values were calculated from median results of apoptosis 
assays.
RESULTS
Myeloma cell lines are resistant to hypoxia-induced apoptosis in vitro
Because patient MM tumor cells specifically engraft within the hypoxic BM 
microenvironment, we anticipated that patient-derived MM cell lines would also exhibit 
resistance to hypoxia-mediated apoptosis in vitro. This was confirmed by analyzing the 
sensitivity of a panel of MM cell lines cultured under various pO2 concentrations in 
increments from 2% down to 0.1% O2 and for various time points up to 72 hours. We chose 
these experimental ranges because these values fell within the actual pO2 ranges reported by 
Spencer et al (6) from in situ measurement in mouse bone marrow. In their study, O2 levels 
in the marrow were found to be <32 mm Hg, but in some bone marrow niches, it could be as 
low as 9.9 mm Hg (or about 1% O2 with a range of 2 - 0.6% measured in the extra-vascular 
spaces). We found that at O2 levels greater than ~1%, only modest cytotoxicity was 
observed, even when cells were cultured out to 72 hours. Only at very low oxygen 
conditions (i.e. 0.5 – 0.1% O2), did we see significant levels of hypoxia-mediated apoptosis 
of the MM cells tested when compared to the “normoxia-cultured” controls. As shown in 
Fig 1A, 8226 and U266 cell lines were the most resistant to low pO2 (~15–20% apoptosis), 
whilst H929 and MM1.S were intermediately sensitive (~25–35% apoptosis) to hypoxia-
mediated apoptosis (all measured at 72 hours). In contrast, OPM-2 cells were the most 
sensitive (>50% apoptosis) to low O2, and this effect occurred significantly earlier, by 48 
hours.
Culturing cells under low pO2 had different effects on the HIFα-subunits expression in the 
nuclear and cytoplasmic fractions of the hypoxia-resistant (8226) and hypoxia-sensitive 
(OPM-2) cell lines cultured under standard normoxic (~22% O2) or hypoxic (0.1% O2) 
Mysore et al. Page 6
Mol Cancer Res. Author manuscript; available in PMC 2017 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
conditions. As shown in Fig 1B (left panel), HIF1α was constitutively expressed in the 
nuclear fraction of 8226 cells as well as significantly upregulated under hypoxic conditions 
(measured at 24 hours). In contrast to 8226, baseline HIF1α was absent in OPM-2 cells, but 
was strongly induced by low O2 (Fig 1B, right panel). On the other hand, HIF2α was 
constitutively expressed in both 8226 and OPM-2 cells and this was independent of O2-
levels (Fig 1B). The rapid upregulation of HIF1α in OPM-2 cells was confirmed using the 
hypoxia mimic, CoCl2, which induced HIF1α expression by 1 hour and reached a maximum 
by 18 hours (Fig 1C). A strong O2-dependent induction of HIF1α was also noted in MM1S, 
H929, and U266 cell lines (Fig 1D), while HIF2α expression was independent of O2 levels 
in H929 and U266 cells, but not in MM1S cells. These findings are generally similar to 
other reports describing HIF expression in MM cells (3, 26). Low pO2 (0.1% 24hrs) did not 
affect the expression of the pro-survival factor Bcl-2, but did inhibit Bcl-xl and MCL-1 in 
OPM-2 and 8226, whilst survivin was only downregulated in OPM-2 cells (Fig 1E). 
Survivin has been reported to play a role in HIF-regulated survival of MM and may be an 
important target for future studies (27). Low pO2 also upregulated the pro-apoptotic factors, 
BNIP3 (a known HIF target) and BID in both lines tested, but BAX was only upregulated in 
OPM-2.
Since we observed differential oxygen-dependent expression patterns for the HIFα-subunits, 
we next asked if expression in the PHD isoforms responsible for regulating the α-subunits 
could explain these results. As seen in Fig 2A, expression of PHD2/EGNL1 was absent in 
8226, but strongly expressed in OPM-2 cells. It has been reported that PHD2/EGLN1 
preferentially hydroxylates HIF1α (28), and its absence would explain why 8226 cells 
express constitutive HIF1α under normoxic conditions. Along similar lines, we also found 
that PHD3/EGLN3, which preferentially hydroxylates HIF2α (29), was absent in both 8226 
and OPM-2 cells, and that also explains the oxygen-independent expression of HIF2α in 
both these cell lines. To ensure that our antibodies could identify PHD/EGLN3 antigens, we 
included a positive internal EGLN3 control (EGLN3 overexpressing lysate from HEK293T 
cells purchased from NOVUS) in our immunoblots. We also found that low pO2 (0.1%) 
significantly upregulated PHD2/EGLN1 protein expression, and probably this likely acts as 
a negative feedback mechanism to return HIF back to basal levels when O2 levels return 
back to normal (30). Furthermore, hypoxia-mediated upregulation of PHD2/EGLN1 was 
unaffected by treatment with HIF-PA. We also examined the expression of another O2-
dependent regulator of HIF1α, the factor inhibiting HIF-1 protein (FIH), and found that 
there was no difference in expression under either normoxic or hypoxic conditions in the 
cell lines we tested.
To further characterize the expression patterns of PHD2/EGLN1, we used the Oncomine 
tool, a publically available cancer microarray database to query if there were differences in 
gene expression in clinical specimens of MM or monoclonal gammopathy of undetermined 
significance (MGUS) versus normal controls within two data sets; Zhan et al (N=78 
samples) (31) and Agnelli et al (N=158) (32). As shown in Figure 2B, PHD2/EGLN1 (top 
panel) was significantly overexpressed in MM specimens versus normal specimens 
(p<0.05), and in MGUS versus normal specimens in the Zhan study (p<0.05) but not in the 
Agnelli study (p>0.05). On the other hand, PHD3/EGLN3 (bottom panel) was not 
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significantly different in MM and MGUS versus normal specimens (p>0.05) in either data 
set, although there was a general downward trend of expression of this gene. Next, we used 
the TaqMan® Array Human Hypoxia 96-well assay system to analyze for changes in a 
subset of hypoxia-related genes in 8226 cells. As shown in Fig 2C, hypoxia increased the 
relative expression of HIF1α by 6 fold, but had only minor effects on HIF2α expression, 
mirroring the results shown in Fig 1B. Other genes associated with the HIF regulatory 
pathway, such as PHD2/EGLN1, cullen-2 and EP300, were induced, whilst PHD3/EGLN3 
and E3 ubiquitin were downregulated and which mirrored the results from Fig 2A and 2B 
above. Not unexpectedly, VEGF and angiopoieitin-4 gene expression, genes that are well 
known to be sensitive to hypoxia, were upregulated by hypoxia.
HIF-targeting polyamide (HIF-PA) inhibits the adaptive hypoxic response in MM cells
We next tested the ability of HIF-PA to inhibit the cellular response to hypoxia using 8226 
cells that had been stably transduced with a hypoxia response element (HRE)-luciferase 
reporter construct (8226-HRE-LUC). As shown in Fig 3A, culturing 8226-HRE-LUC cells 
under low pO2 (0.1% O2, 24hr) resulted in a ~2 fold induction of luciferase activity over the 
baseline “normoxic” controls. This hypoxia-mediated LUC induction was significantly 
inhibited (p<0.05) by treatment with HIF-PA but not by a control polyamide (CO-PA) that 
recognized a non-HRE sequence. To provide further support for our model, we knocked 
down HIF1α expression in 8226-LUC cells using HIF1α siRNA (Fig 3B top panel). As we 
expected, and as shown in Fig 3B (bottom panel), the hypoxia-mediated increase of LUC 
activity in 8226-LUC reporter cells transfected with HIF1α siRNA also demonstrated a 
significant inhibition of the hypoxia-induced LUC activity. These data support our 
hypothesis that HIF-PA can specifically inhibit the HIF-mediated cellular response to 
hypoxia in 8226 cells. Next we showed that HIF-PA could inhibit the expression of HIF-
mediated gene expression using real-time PCR to assay for the effect of HIF-PA treatment 
on the expression VEGF RNA. It is well known that hypoxia upregulates VEGF 
transcription in myeloma cells, and as expected, culturing 8226 cells under hypoxic 
conditions (0.1% O2, 24 hrs) induced VEGF mRNA by ~3–4 fold (Fig 3C). Treatment with 
HIF-PA significantly (p<0.05) inhibited this hypoxia-mediated upregulation of VEGM 
mRNA in a dose dependent manner. This effect on mRNA was also mirrored by HIF-PA 
mediated inhibition of VEGF protein (measured by ELISA) in the supernatant of these cells 
(Fig 3D). Altogether, these data demonstrate that HIF-PA specifically and effectively 
inhibits the adaptive hypoxic response in MM cells.
HIF-PA treatment overcomes MM cell resistance to hypoxia
We next asked if inhibiting the hypoxic response with HIF-PA could sensitize a panel of 
MM cells to hypoxia-mediated killing. We assayed this using hypoxia resistant 8226 and 
U266 cells and hypoxia sensitive MM1.S and OPM-2 cells that were cultured under 
normoxic or hypoxic conditions (0.1% O2) in the presence of HIF-PA or a control 
polyamide (CO-PA). HIF-PA had little effect on 8226 cells (Fig 4A) and U266 (Fig 4B) 
cultured under standard conditions (white bars), but the treatment of 8226 and U266 cells 
cultured under hypoxic conditions resulted in significant and dose-dependent hypoxia-
mediated killing (an increase from ~20% to ~60%) (black bars) (ANOVA *p<0.05). The 
hypoxia “sensitive” MM1.S and OPM-2 cells (Fig 4C and D) were even more responsive to 
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HIF-PA, (ANOVA *p<0.05) with a similar increase in apoptosis observed by only 24 hrs 
when cultured under low O2 conditions. The CO-PA compound had little, if any, effect on 
the hypoxia-mediated apoptosis in any of the cell lines examined. These data support our 
hypothesis that inhibiting the adaptive hypoxic response with HIF-PA overcomes MM 
resistance to hypoxia-mediated apoptosis in vitro.
As an in vivo correlate of the above in vitro data, we tested HIF-PA activity using a 
xenograft SQ MM tumor model in NOD/SCID mice (21, 24, 33). The mice were challenged 
on the flank with 10 X106 8226 cells admixed with matrigel. Once a palpable tumor 
developed (~15 days later), the mice were randomized into groups (N=10 mice/group) to be 
given 5 IP injections of either HIF-PA (100 nmol/injection) or vehicle control every other 
day (Fig 5A, arrows on X-axis indicate days of treatment). The HIF-PA treatments were 
well tolerated, with only a small transient decrease in weight being observed, and induced a 
rapid and significant inhibition of tumor growth in the HIF-PA-treated mice compared to 
control mice (p<0.05). In order to confirm uptake of HIF-PA, we treated an additional group 
of mice (N=2 mice/group) with a FITC-conjugated HIF-PA and measured drug uptake by 
real-time fluorescent imaging. We observed some auto-fluorescence signal in the bladder 
and gut (Supplemental Figure 1A, mice #1 and #2). However, in FITC-HIF-PA treated mice, 
positive signals were also observed in the tumor nodules (Supplemental Figure 1A, note 
arrow indicating tumor nodule in mouse #3 and #4). Labeled HIF-PA localization in the 
nuclei was confirmed by fluorescent confocal microscopy of excised tumor sections, 
costained with DAPI (Supplemental Figure 1B). This is consistent with the recent studies on 
the uptake C14 labeled Py-Im polyamides into tumors (34)
In order to characterize the in vivo effect of HIF-PA, we excised the tumor nodules 24 hrs 
after the last injection and performed immunohistochemistry on serial sections stained either 
for hypoxia (pimonidazole staining, left panels) or apoptosis (cleaved caspase 3, right 
panels) (Fig 5B). Both vehicle control (top left panel) and HIF-PA (bottom left panel) 
treated tumors had regions of hypoxia (brown stained areas), but the extent of hypoxia was 
significantly greater in the HIF-PA treated tumors than in the control tumors (quantified in 
Fig 5C). We also noted there were significantly greater areas of necrosis within the tumor 
bed in HIF-PA treated tumors compared to control tumors as well as a strong physical 
correlation between areas of hypoxia and presence of apoptosis in the HIF-PA-treated 
tumors (see Fig 5B, bottom right panel). In contrast, apoptotic cells were evenly distributed 
throughout the tumor bed in the control tumors (Fig 5B, top right panel) and were not 
localized to a specific geographic region in the tumor. As shown in Fig 5C, we found that 
the area of positive hypoxia staining in tumor sections (10 tumors/group, 10 fields/tumor) 
was ~35% in nodules harvested from the HIF-PA treated mice, compared to about 18% in 
the tumors harvested from mice treated with vehicle control (p<0.05). The apoptotic index 
(AI) in both the normoxic or hypoxic regions of the tumor was determined by counting 
number of apoptotic cells in these regions using corresponding serial sections (10 tumors/
group, 10 fields/region) stained with pimonidazole to identify the specific geographical 
regions of interest. As shown in Fig 5D, there was an approximate 3–4 fold increase in 
apoptotic cells located within the hypoxic regions of tumors from the HIF-PA treated mice 
compared to hypoxic regions of the control tumors (P<0.05), whilst there was no difference 
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in apoptotic index within “normoxic” regions of the tumor bed. Finally, we examined the 
expression of VEGF in tumor lysates by ELISA (Fig 5E). As with our in vitro data (see Fig 
3D), HIF-PA significantly inhibited VEGF expression by approximately 50% when 
compared to control tumors. Altogether, this data supports our hypothesis that HIF-PA can 
overcome resistance to hypoxia-mediated apoptosis in vivo by inhibiting the adaptive 
hypoxic response.
As a more physiologically relevant model, we developed an orthotopic, “disseminated” bone 
marrow-engrafted xenograft model based on the model developed by Miyakawa (35) using 
LUC2-transfected 8226 (these cells use a different p4.5 LUC2 plasmid to drive luciferase 
expression and thus are different than the 8226-HRE-LUC cells described above) allowing 
us to perform real-time longitudinal studies on myeloma tumors engrafted in the BM. As 
shown in Supplemental Fig 1A, NOG mice challenged with 8226LUC cells developed bone 
marrow engrafted MM tumors that could be observed by bioluminescence (top panel) and 
X-ray (bottom panel) analysis. Approximately 20–50% of the bone marrow cells from 
inoculated mice were positive for human CD45 confirmed by flow cytometry using FITC-
conjugated anti-huCD45 antibody (Supplemental Fig 2B) and by IHC of in situ huCD45+ 
8226 cells in the mouse femurs (Supplemental Fig 2C). Gross histological analysis of the 
mice didn’t show tumor formation in other tissues (i.e. liver, lung, spleen, or kidney).
We then asked if treatment with HIF-PA had an anti-MM effect on tumor cells in the bone 
marrow. As shown in Fig 6A, approximately +20 days post challenge with 8226-LUC cell, 
engraftment of LUC2+ cells in the skeleton was confirmed and the mice were then 
randomized into treatment groups (6–8 mice/group). The mice were then give IP injections 
of 100 nmol/injection of HIF-PA every other day (arrows indicate days of injection on day 
+27, +29 +31, +34, +36 and +38) or vehicle control. The average radiance 
(photons/sec/cm2/steradian) was measured at various time points using a Perkin Elmer 
Lumina XRMS small animal imager (out to day +40). The treatment with HIF-PA 
significantly inhibited MM tumor growth in the marrow (data is presented as average 
radiance ± 95% confidence intervals) starting after the third injection and reaching statistical 
significance by the last HIF-PA injection on day +38). It should be noted that this particular 
HIF-PA treatment regimen was not able to delay the development of hind limb paralysis (the 
main end point criteria) when compared to control animals, with ~50% of the animals 
reaching their end point on day +59 (control mice) and day +62 (HIF-PA treated mice). 
Representative images of some of the mice are shown for day +22, +35 and +40. We noted a 
decrease in the luciferase activity as well as a general shrinkage of individual tumor foci in 
the mice. Specifically, in control mice, tumor foci tended to grow and merge over time, 
while in HIF-PA treated mice, the foci remain relatively small and isolated.
Effect of targeting the mTOR pathway on regulation of HIF-PA sensitivity
Since we have previously demonstrated that mammalian target of rapamycin (mTOR) 
inhibitors kill MM cells in vivo, and this anti-MM effects is mediated, at least in part, by 
inhibiting VEGF translation and de novo angiogenesis (21, 24, 33, 36), we asked if there 
would be a synergistic effect if we combined HIF-PA-mediated inhibition of hypoxia-
inducible gene transcription in combination with rapamycin-mediated inhibition of mTOR-
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mediated regulation of protein translation. As shown in Fig 7A, treatment of 8226 cells with 
the mTOR inhibitor rapamycin had a modest effect on apoptosis in MM cells cultured under 
normoxic or hypoxic conditions (0.1% O2, 72 hours). However, under low pO2 conditions, 
using median effect combination indices (CI) analysis for apoptosis induction, we found that 
the combination treatment with rapamycin and HIF-PA resulted in synergistic drug 
interactions with CI values <1 across several concentrations tested. Altogether, this suggests 
that targeting both transcription and translation of hypoxia-induced genes may be an 
effective anti-MM strategy (Fig 7A see grey and black bars and bracketed area). We also 
asked if REDD1, a hypoxia-sensitive negative regulator of mTOR, was affected by low pO2 
in both 8226 and OPM-2 cells. As shown in Fig 7B, REDD1 was strongly induced in MM 
cells. Furthermore, the functional effects of hypoxia on mTOR signaling demonstrated a 
marked inhibition of phosphorylation of p70S6 kinase but only modest effects on AKT 
phosphorylation. The effects of hypoxia-mediated inhibition on p70 was transient and 
reversible in OPM-2 cells, with p70 (389) phosphorylation levels rapidly returning to normal 
within 2 hrs following reoxygenation of the cells (Fig 7C).
Discussion
There is increasing evidence that low oxygen conditions are supportive of MM growth, 
progression and the development of resistance to chemotherapy, and that this occurs via a 
cellular adaptive hypoxic response mediated, at least in part, by the action of HIF-
transcriptional factors. Because of this and the development of more resistant tumor 
phenotypes associated with hypoxia, there has been increasing interest in targeting HIF-
mediated gene transcription to overcome these effects (18). Hypoxia induces the expression 
of about ~100–200 genes mostly related to metabolism, angiogenesis, and apoptosis (37, 
38), and in this study, we found that a sequence-specific DNA-binding oligomer (HIF-PA) 
that is capable of binding to the HRE and inhibiting HIF-mediated gene transcription (19, 
39) can overcome MM resistance to hypoxia-mediated apoptosis in vitro and in vivo. We 
also found that treating MM cells with a combination of HIF-PA, to inhibit gene 
transcription, and rapamycin, to inhibit gene translation, had a strong synergistic cytotoxic 
effect against MM tumor cells cultured under hypoxic conditions. Our results provide a 
strong pre-clinical rationale for using polyamides to target the adaptive hypoxic response in 
MM and may prove to be efficacious in treating myeloma tumors engrafted in the hypoxic 
bone marrow microenvironment. We also note that the ability of HIF-PA to recognize and 
bind to HRE sequences enables them to block both the HIF1α/HIF1β and HIF2α/HIF1β 
dimers.
We surveyed a panel of MM cell lines and found that the expression of the HIF1α-subunit 
was generally absent under normal culturing conditions but was rapidly increased by low 
pO2 levels. The exception to this was 8226 cells, which constitutively expressed HIF1α 
under normoxic conditions, although it was further upregulated by hypoxia. In contrast to 
the HIF1α-subunit, HIF2α was constitutively expressed in all the cell lines studied (except 
MM1S), and the expression levels were independent of O2 levels. Of note, we did not 
observe a correlation between the expression of the HIF1α-subunit and sensitivity to 
hypoxia-mediated cytotoxicity in the cells we examined. These results are interesting 
because they suggest that the HIFα-subunits are differentially regulated by low pO2 levels in 
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MM cells and that mechanisms other than just the expression of HIF1α regulates sensitivity 
to hypoxia. In fact, despite their similarities, it is known that the α-subunits can mediate 
different responses to hypoxia and tumorogenesis: HIF1α acts as a tumor suppressor gene 
and inhibits tumor growth, whilst HIF2α acts as an oncogene and promotes tumor growth 
(3, 40). It has also been demonstrated that the different α-subunits have varying affinities for 
hydroxylation by the different PHD isoforms, with PHD2/EGLN1 showing the highest 
affinity for HIF1α (28) and PHD3/EGLN3 showing the highest affinity for HIF-2α (29). In 
our study, we found that the expression patterns of PHD/EGLN isoforms could explain 
HIFα-subunit expression in both 8226 and OPM-2 cells. Specifically, PHD2/EGLN1 was 
expressed at very low levels in 8226, but not in OPM-2, which can explain why HIF1α was 
constitutively expressed in the former but not the later. It is also likely that the absence of 
PHD3/EGLN3 in MM cells results in the inability to hydroxylate HIF2α, thereby rendering 
its expression independent of O2 levels. Thus, it is likely that the expression and ability of 
PHD isoforms to regulate the expression of the different α-subunits may have important 
ramifications for disease progression and pathology in MM, such as what is observed in 
patients with VHL-cancer syndrome (41). In support of this, PHD3/EGLN3, but not PHD2/
EGLN1 silencing has been reported at a relatively high frequency for patients with MM, 
Waldenström’s macroglobulinaemia and monoclonal gammopathy of undetermined 
significance and that these patients have a poorer prognosis (42) suggesting that PHD/EGLN 
activity is as important as HIF activity in regulating the adaptive hypoxic responses in MM, 
and is something that we will pursue in future experiments.
There is a dynamic physiological process that exists between the metabolic needs of tumor 
cell growth and the sufficiency of the vascular networks that are required to support these 
needs. On one hand, the development of oxygen stress within the tumor inhibits cell division 
and growth and induces cell death, but on the other hand, hypoxia activates the HIF-
mediated cellular responses that provide protective growth and survival advantages and that 
can foster the development of tumor resistance to radiation and chemotherapy (27, 43). In 
this study, we found that HIF-PA was well tolerated by mice, localized to the nuclei of the 
tumor xenografts, and could inhibit tumor growth. Histological analysis of HIF-PA treated 
SQ xenografts indicated that tumor cytotoxicity was remarkably co-localized with regions of 
ischemic stress in the tumor nodules and that VEGF expression was significantly inhibited. 
While VEGF is clearly a factor in the induction of the HIF-PA-mediated killing of MM 
tumor cells, we believe that VEGF is probably only one of many genes affected by targeting 
the adaptive hypoxic response using HIF-PA (39). While our SQ model demonstrated some 
efficacy of HIF-PA in reducing solid MM xenograft tumors, we recognize that this 
particular model may not be physiologically relevant to clinical myeloma, which engrafts in 
the bone marrow. Therefore, we also present data using an orthotopic MM xenograft model. 
In this model, 8226 tumor cells localized to the mouse BM demonstrate a similar anti-tumor 
response to HIF-PA treatment that mirrored the effects seen in our SQ model. Specifically, 
we noted a decrease in luciferase activity measured by the change in average radiance, as 
well as a general decrease in the size of the MM tumor foci engrafted in the bone marrow. 
While HIF-PA had a statistically significant effect on orthotopic MM tumors, this did not 
translate to a longer survival in the mice. We believe that this may be because our initial 
HIF-PA treatment strategy was not the most effective dosing regimen for establishing and 
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maintaining long term anti-myeloma responses in our orthotopic model. For example, HIF-
PA availability and clearance in the bone marrow still needs to be established. This, in fact, 
has important ramifications for addressing the known limitations of these anti-angiogenesis 
therapies (44), because HIF-PA directly targets the hypoxic response at the level of gene 
transcription, rather than targeting a single downstream effector of hypoxia, such as VEGF.
Because of our previous in vivo studies (21, 24, 33, 36) that demonstrated a correlation 
between the anti-angiogenic effects of the mTOR inhibitor, temsirolimus, we initially 
hypothesized that hypoxic stress alone would be sufficient to kill MM cells. However, we 
found that MM cell lines are generally resistant to low O2, suggesting that hypoxia-induced 
physiological stress alone cannot fully explain our results. In fact, myeloma cells that are the 
most resistant to mTOR inhibition (e.g. 8226 and U266), are also the most the resistant to 
hypoxia, whilst cells that are more sensitive to rapalogs, such as OPM-2 are the most 
sensitive hypoxia-mediated killing (45). It is also known that hypoxia regulates the activity 
of mTOR via the induction of REDD1 (46) although the relationship between hypoxia, 
mTOR activation, and HIF expression/activation remain complex and is not fully 
understood (47). This is further confounded by the presence of cap-independent, IRES-
mediated translational pathways (48, 49) that may allow tumor cells to escape mTOR-
targeting therapies. Interestingly, we find that the combination of polyamides and rapamycin 
can effectively synergize with each other to overcome resistance to hypoxia-mediated killing 
of 8226 cells in vitro. Along another line of reasoning, we noted that in a recent study by 
Maiso et al (10), hypoxic conditions conferred a striking resistance to bortezomib-mediated 
apoptosis in MM cell lines and, critically, inhibiting HIF1α expression could restore 
sensitivity. If true, then we hypothesized that HIF-PA would likely have a similar effect in 
bortezomib-treated cells by inhibiting the adaptive hypoxic response and overcoming any 
hypoxia-mediated resistance to this drug. However, despite our best efforts, we were unable 
to replicate this phenomenon, and instead found that our results were more similar to those 
reported by Hu et al (50) which found instead that bortezomib killed MM cell lines cultured 
under hypoxic conditions. It is unclear why our experiments differed from those of Maiso et 
al, but could reflect variations in how hypoxic conditions were established. Therefore, at 
least in our hands, it remains to be shown if hypoxia confers resistance to chemotherapeutic 
drugs and if HIF-PA can overcome and sensitize MM cells by inhibiting HIF-activity.
In summary, HIF and related hypoxic response factors are frequently upregulated in MM 
tumors, and has been implicated in contributing to the development and prognosis of MM 
(15). The induction of pro-angiogenic, proliferative, metastatic, and glycolytic genes by 
HIF1 may also be involved in the development of chemotherapy resistant phenotypes (10, 
27). In this sense, HIF1, and in particular the expression of the different α-subunits, may 
play dual roles in the survival and progression of MM, through the differential α-subunit 
expression patterns and the genes that they activate. Thus, we argue that understanding the 
role and mechanisms HIF1-mediated adaptive hypoxic response at the level of HIF1/DNA 
binding could be clinically relevant for developing novel therapies against patient MM 
engrafted in the hypoxic bone marrow environment.
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Implications
Pyrrole-imidazole (Py-Im) polyamides target and disrupt the adaptive hypoxic responses 
in MM cells that may have clinical significance as a therapeutic strategy to treat myeloma 
engrafted in the bone marrow microenvironment.
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Figure 1. 
Cytotoxic effects of low pO2 levels on myeloma cell lines. (A) The % apoptosis (measured 
by cleaved caspase 3) following 72 hour culture of myeloma cells under “normoxic” 
conditions (~22% O2, 5% CO2) or hypoxic (0.1% O2, 5% CO2) conditions, except for 
OPM-2 cells which were cultured for 48 hours. Brackets indicate P<0.05 (T-test). Values 
represent mean ± 1 standard deviation of 4 independent experiments/cell line. (B). 
Immunoblots of HIF1α and HIF2α-subunit expression in 8226 and OPM-2 cells cultured 
under normoxic or hypoxic conditions (0.1% O2, 5% CO2) for 24 hours. The cells were 
harvested on ice then the cytoplasmic and nuclear fractions were isolated, and the lysate was 
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immunoblotted for indicated proteins. C=cytoplasm fraction, N=nuclear fraction. The data 
presented are a representative immunoblots of at least 2 independent experiments. (C) Time 
course of CoCl2-mediated induction of HIF1α expression in OPM-2 cells. Cells were 
cultured with 100nM CoCl2 or vehicle control and the cellular lysates were harvested at 
indicated time points and immunoblotted for HIF1α expression. The data presented are a 
representative immunoblots of at least 2 independent experiments. (D) Hypoxia-mediated 
induction of HIF1α and HIF2α in MM1S, H929 and U266 myeloma cell lines cultured 
under normoxic or hypoxic (0.1% O2, 5% CO2) conditions for 24 hours. Cells were 
harvested on ice and the cell lysate was immunoblotted for HIF1α and HIF2α. The data 
presented are a representative immunoblots of at least 2 independent experiments. (E) 
Immunoblots showing hypoxia-mediated changes in survival-related protein expression in 
8226 and OPM-2 cells cultured under normoxic or hypoxic conditions (0.1% O2, 5% CO2) 
for 24 hours. The cells were harvested on ice and the lysate was immunoblotted for 
indicated proteins. The data presented are a representative immunoblots of at least 2 
independent experiments.
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Figure 2. 
There is differential expression of HIF regulatory pathway in 8226 cells. (A) Immunoblots 
of PHD2/EGLN1, PHD3/EGLN3 and FIH in 8226 cultured under normoxic or hypoxic 
conditions (0.1% O2, 5% CO2) for 48 hours in the presence or absence of HIF-PA (10 μM). 
Cells were harvested on ice and the cell lysate was immunoblotted. A positive immunoblot 
control (an over expression lysate from HEK293T cells) for PHD3/EGLN3 is included. The 
data presented are a representative immunoblots of at least 2 independent experiments. (B) 
Boxplot results showing a meta-analysis of PHD2/EGLN1 and PHD3/EGLN3 in normal 
bone marrow, monoclonal gammopathy of undetermined significance (MGUS), multiple 
myeloma, smoldering myeloma and plasma cell leukemia. Analysis was performed using 
Oncomine and includes two data sets: Angelli et al (N=156) and Zhan et al (N=78). (C) 
Relative fold change in hypoxia-mediated expression of select genes compared to normoxic 
conditions. The 8226 cells were cultured under normoxic or hypoxic (0.1% O2, 5% CO2) 
conditions for 24 hours. The RNA was collected and gene expression was determined by 
quantitative real-time PCR analysis. The relative fold change in hypoxia-mediated gene 
expression compared to normoxic levels are shown. Values above the dotted line indicate 
upregulation of genes by hypoxia, and values below the dotted line indicate downregulation 
of genes by hypoxia. These data are representative of 2 independent experiments.
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Figure 3. 
HIF-PA polyamide inhibits the in vitro response to low pO2 in 8226 myeloma cell lines. (A) 
8226-HRE-LUC reporter cells were cultured under normoxic or hypoxic (0.1% O2, 5% 
CO2) conditions and treated with either 10 μM HIF-PA or 10 μM CO-PA for 24 hours. 
Luciferase activity in cell extracts was measured using a luminometer. Values are presented 
as means ± 1 standard deviation of 3 independent experiments. Bracket with *=P<0.05 
(ANOVA). Bracket with NS= not significant. (B) 8226-HRE-LUC reporter cells were co-
transfected with HIF1α siRNA or scrambled (sc) control and were then cultured under 
normoxic or hypoxic (0.1% O2, 5% CO2) for 24 hours. Luciferase activity in cell extracts 
was measured using a luminometer. Values are presented as means ± 1 standard deviation of 
3 independent experiments. Bracket with *=P<0.05 (ANOVA). Bracket with NS= not 
significant. Top panel: Immunoblot demonstrating knockdown of HIF1α (but not HIF2α) by 
siRNA. These data are representative of 3 independent experiments. Bottom panel: Change 
in LUC activity in treated 8226 cells. Values are presented as means ±1 standard deviation 
of 3 independent experiments. Bracket with *=P<0.05 (ANOVA). Bracket with NS= not 
significant. (C) HIF-PA (10 μM)-mediated inhibition of VEGF mRNA levels in 8226 cells 
cultured under normoxic or hypoxic (0.1% O2, 5% CO2) conditions for 24 hours. VEGF 
mRNA levels were measured by quantitative real-time PCR of 3 independent experiments. 
*P<0.05. (ANOVA). (D). Effect of HIF-PA treatment on VEGF protein in supernatants of 
8226 cells cultured under normoxic or hypoxic conditions were measured by ELISA. Values 
are presented as mean ± 1 standard deviation of 3 independent experiments. *P<0.05 
(ANOVA).
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Figure 4. 
HIP-PA treatment sensitizes the hypoxia-resistant 8226, U266, and hypoxia-sensitive 
MM1S and OPM-2 cells to hypoxia-mediated apoptosis in vitro. (A) 8226 were cultured 
under normoxic or hypoxic (0.1% O2, 5% CO2) conditions with indicated concentration of 
HIF-PA or CO-PA for 72 hours. (B) U266 were cultured under normoxic or hypoxic (0.1% 
O2, 5% CO2) with indicated concentration of HIF-PA or CO-PA for 72 hours. (C) MMI.S 
cells were cultured under normoxic or hypoxic (0.1% O2, 5% CO2) with indicated 
concentration of HIF-PA or CO-PA for 48 hours. (D) OPM-2 cells were cultured under 
normoxic or hypoxic (0.1% O2, 5% CO2) with indicated concentration of HIF-PA or CO-PA 
for 24 hours. At the end of the treatment, cells were harvested and the percent apoptosis was 
measured by flow cytometry for cleaved caspase 3. Values are mean ± 1 standard deviation 
of 3 independent experiments. Bracket * indicates significant change (P<0.05) (ANOVA) of 
treatment compared to control.
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Figure 5. 
HIF-PA (100nmol/kg mouse) inhibits 8226 tumor growth in a subcutaneous (SQ) myeloma 
xenograft model (N=10 mice/group). (A) Change in 8226 tumor volume in HIF-PA-treated 
NOD/SCID mice. Mice were challenged SQ with 10×106 cells admixed in matrigel. When 
the tumor volume was ~500 mm3 (~day 15 post challenge), the mice were randomized into 
treatment and control groups (10 mice/group). The mice were given 5 IP injections at 
indicated concentration (Arrows indicate days of treatment) and the tumor volume was 
measured using calipers. Values represent mean volume ± 95% confidence interval. 
*P<0.05. (B) Photomicrographs of SQ tumor sections harvested from mice treated with HIF-
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PA or vehicle-control treated mice (N=10 mice/group). Tumors were harvested 24 hours 
after last the IP injections. Serial tumor sections were stained for hypoxia (by pimonidazole; 
brown stained areas) or apoptosis (cleaved caspase 3). *Indicate corresponding geographic 
regions in the sections. Arrow indicates areas of hypoxia and associated apoptosis. (C) The 
percent area of hypoxic tumor bed measured by staining with pimonidazole (measured in 10 
fields/tumor, 10 tumors/group) in 8226 tumors harvested from HIF-PA or vehicle-treated 
mice. Area was measured using Metamorph computer software. Values are presented as 
mean ± 1 standard deviation. *P<0.05. (ANOVA) (D) Apoptotic index (the number of 
apoptotic cells/unit area) was measured by counting cells staining for cleaved caspase 3 (10 
fields/tumor, 10 tumors/group). The apoptotic index in regions of “normoxia” or “hypoxia” 
were assayed by using serial sections stained with pimonidazole to identify specific 
geographical areas in the tumor nodules. Values are presented as mean ± 1 standard 
deviation. *P<0.05 (ANOVA). (E) Tumor lysate was collected and VEGF was analyzed by 
ELISA (10 tumors/group). Values are presented as mean ± 1 standard deviation. *P<0.05 
(T-test).
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Figure 6. 
HIF-PA (100nmol/kg mouse) inhibits 8226-LUC tumor growth in an orthotopic myeloma 
xenograft model (N=8 mice/group). (A) Change in average radiance (p/sec/cm2/ser) in HIF-
PA-treated NOG mice was measured using IVIS XRMS small animal imaging system. 
Briefly, mice were challenged IV with 10×106 cells and engraftment of 8226-LUC cells 
were confirmed by IP injection of luciferin substrate (VivoGlo, Promega) starting ~day 20 
post challenge. Once a positive signal was observed in the bone marrow, the mice were 
randomized into treatment and control groups (6–8 mice/group). The mice were given 6 IP 
injections at indicated concentration (Arrows indicate days of treatment) and the change in 
average radiance of tumor foci were measured as described above. Values represent mean 
volume ± 95% confidence interval. *P<0.05. (B) Representative images of mice imaged on 
day +22, +35 and +40 showing changes in LUC activity. Mice were imaged using a IVIS 
XRMS small animal imaging system.
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Figure 7. 
Combination of rapamycin and HIF-PA can overcome resistance to hypoxia-mediated 
apoptosis in 8226 cells. (A) 8226 cells were cultured under normoxic (22%O2, 5% CO2) or 
hypoxic (0.1% O2, 5% CO2) and treated with the indicated concentrations of rapamycin, 
HIF-PA or both for 24 hours. At the end of the treatment, cells were harvested and % 
apoptosis was measured by flow cytometry for cleaved caspase 3. Values are mean ± 1 
standard deviation of 3 independent experiments. Bracket * indicates significant change 
(P<0.05) of treatment compared to control (ANOVA). The effect of combining HIF-PA with 
rapamcyin on induction of apoptosis was assessed by the median effect method using 
Calcusyn Software Version 1.1 (Biosoft, Cambridge, United Kingdom). Combination 
indices (CI) values were calculated using the most conservative assumption of mutually 
nonexclusive drug interactions. CI values were calculated from median results of apoptosis 
assays. (B) Immunoblots of mTOR-related signaling proteins in 8226 and OPM-2 cells 
cultured under normoxic or hypoxic conditions for 24 hours. The data presented are a 
representative immunoblots of at least 2 independent experiments. (C) Time course of 
p70S6 kinase phosphorylation in OPM-2 cells following re-oxygenation. Cells were cultured 
under hypoxic conditions (0.1% O2, 5% CO2) for 24 hours, then cultured under normoxic 
conditions (22% O2, 5% CO2). Cell lysates were harvested at indicated time points and 
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immunoblotted for HIF1α and phospho-P79S6K (389) expression. The data presented are a 
representative immunoblots of at least 2 independent experiments.
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